The Medicines Company (TMC) is a biopharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the worldwide hospital marketplace. The company operates in the Americas, Europe, the Middle East, and Asia Pacific regions. The company's products include: Angiomax (bivalirudin), Minocin IV, Orbactiv and Ionsys (fentanyl iontophoretic transdermal system). The Medicines Company markets, Angiomax, an intravenous direct thrombin inhibitor, which is a peptide compound, from Biogen Idec, Inc. (Biogen Idec). It has license rights to develop, market and sell Angiomax globally. It markets Angiomax in the US for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA) and for use in patients undergoing percutaneous coronary intervention (PCI), including patients with risk of heparin induced thrombocytopenia and thrombosis syndrome (HIT/HITTS). In FY2016, the net sales of Angiomax amounted to US$50.5 million, which accounted for 30.1% of the company’s total revenue. In Europe, the company markets Angiox for use as an anticoagulant in patients undergoing PCI, for use in adult patients with acute coronary syndrome (ACS), and for the treatment of segment elevation myocardial infarction (STEMI) patients undergoing primary PCI. Its approval for ACS in Europe also includes patients with unstable angina or non-STEMI planned for urgent or early intervention when used with aspirin and clopidogrel. Angiomax is also approved for sale in Australia, Canada, New Zealand, Russia, India and a number of countries in Central America, South America and the Middle East for PCI indications similar to those approved by the Food and Drug Administration (FDA). In addition, Angiomax is approved in Canada for the treatment of patients with HIT/HITTS undergoing cardiac surgery. The Medicines Company markets Minocin IV, which is a Tetracycline-class antibiotic used for the treatment of bacterial infections due to susceptible isolates of designated microorganisms, including Acinetobacter species. The Medicines Company also markets Orbactiv, an Antibiotic used for treatment of adult patients with acute bacterial skin and skin structure infections, or ABSSSI, caused or suspected to be caused by susceptible isolates of the label-designated gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus, or MRSA. In FY2016, the net sales of Orbactiv amounted to US$16 million and the net sales of Minocin amounted to US$8.7 million. The company’s acute care generic products include IONSYS, RPX-602, APB-700, ALN-PCSsc, Carbavance and MDCO-216. RPX-602 is a proprietary reformulation of Minocin IV utilizing magnesium sulfate that enables administration of minocycline in smaller volumes of fluids, and may improve the local tolerability of intravenous infusions. ABP-700 is an intravenous anesthetic agent being developed for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures. ALN-PCSsc is a subcutaneously administered RNA interference, or RNAi, therapeutic considered to be a PCSK9 synthesis inhibitor which is being developed for the potential treatment of hypercholesterolemia. Carbavance is an antibiotic agent that is used for the treatment of hospitalized patients with serious gram-negative bacterial infections, including complicated urinary tract infections, hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia, and bacteremia. MDCO-216 is a naturally occurring variant of a protein found in human high-density lipoprotein that is licensed from Pfizer. MDCO-216 is a reversal cholesterol transport agent which is used to reduce atherosclerotic plaque burden development. Ionsys (fentanyl iontophoretic transdermal system) is a compact, needle-free patient-controlled system that is developed for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. It is marketed in the US; and the European Union. In FY2016, the net sales of Ionsys amounted to US$0.6 million. The Medicines Company's subsidiaries include The Medicines Company (Australia) Pty Limited, The Medicines Company (Denmark) ApS, The Medicines Company (Italy) S.r.l., The Medicines Company (Leipzig) GmbH, The Medicines Company (Netherlands) BV, The Medicines Company (New Zealand) Limited, The Medicines Company (Spain) S.L., The Medicines Company France SAS, The Medicines Company UK Limited, and Vita Solutions, Inc. Geographically, the company reports its revenue from three regions, namely, the US, Europe and Other. In FY2016, the US region accounted for 93.1% of the company’s total revenue; followed by Europe with 5.6%; and Others with 1.3% revenue.
Scope of the Report
-- About the Company - Historical Details, Current Ownership Structure and basic overview of The Medicines Company in terms of revenue, net income, and operating income.
-- Financials - Details about The Medicines Company listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
-- Company SWOT Analysis - Outlines The Medicines Company’s strengths, weaknesses, and opportunities and threats facing the company.
-- Recent Developments - Showcases The Medicines Company’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
-- Strategic Evaluation - Provides an overview of The Medicines Company’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.
Key Questions Answered
-- What domain does The Medicines Company operate and what are key points about it?
-- What is the product / service portfolio of The Medicines Company?
-- How has The Medicines Company performed financially from the 2013?
-- How does The Medicines Company rank among its peers in terms of revenue and market share?
-- What are The Medicines Company strengths and weaknesses and what opportunities and threats does it face?
-- What are The Medicines Company’s main growth strategies and how successful has the company been at implementing them?
-- What is the in-house technical capability of The Medicines Company? Where does it procure / outsource it?
Reasons to buy
-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
-- 12 hour delivery time fulfilling your urgent requests as per your requirement
-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics
1. About the Company
1.1 History and Basic Facts
1.2 Ownership Structure and Key Executives
1.3 Head Office
1.4 Other Locations & Subsidiaries
1.5 List of Competitors
1.6 Employee Count & Distribution
2.1 Company Type (Listed / Unlisted)
2.2 Annual Statements
2.3 Key Financial Highlights
2.4 Region-wise Breakdown
3. Product / Services
4. SWOT Analysis
4.1 SWOT Overview
5. Recent Developments
5.1 Mergers & Acquisitions
5.2 Partnerships, Collaborations & Joint Ventures
5.3 New Product Launches
5.4 Business Expansion / Divestment
6. Strategic Evaluation
6.1 Corporate Strategy
6.2 Legal Issues
6.3 Analyst Outlook
7. Technology Landscape
-- 7.1.1 Industry Snapshot
-- 7.1.2 IT Spend
-- 7.1.3 Key Information Technology Trends
-- 7.2.1 IT Overview
-- 7.2.2 Key IT Technologies
-- 7.2.3 Recent IT Initiatives
-- 7.2.4 IT Outsourcing Engagements
-- 7.2.5 Key IT Management
-- 7.2.6 CIO/CTO Profile
-- About Us
-- Contact Us
Fig.1: Company Snapshot
Fig.2: Locations Listing on Map
Table.1: Ownership Structure
Table.2: List of Competitors
Table.3: Annual Statements
Table.4: Key Financial Highlights
Table.5: Region-wise Breakdown
Table.6: Product/Services Overview
Table.7: Mergers & Acquisitions
Table.8: Partnerships, Collaborations & Joint Ventures
Table.9: New Product Launches
Table.10: Business Expansion / Divestment
Table 11: IT Budgets
Table 12: Key IT Management (CIO / CTO)
Table 13: IT Deals undertaken in the past years